Navigation Links
Misonix Announces New Distribution Agreement for Taiwan
Date:8/3/2011

FARMINGDALE, N.Y., Aug. 3, 2011 /PRNewswire/ -- Misonix, Inc. (NASDAQ: MSON), a medical device company that designs, manufactures and markets innovative therapeutic ultrasonic products worldwide for wound debridement, spinal surgery, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications, has entered into a new three-year exclusive distribution agreement with Grand Medical Instrument Co., Ltd., based in Taichung, Taiwan, R.O.C., for the distribution of the SonaStar® Ultrasonic Surgical Aspirator and the BoneScalpel™ Ultrasonic Bone Cutter. The agreement provides Grand Medical with the rights to sell in Taiwan, R.O.C., and includes annual minimum purchase requirements.  Open market sales will commence after product registration is completed by Grand Medical, which can take one year or longer.  

Grand Medical has significant experience with launching capital equipment based surgical systems and is well known as a distributor of state-of-the-art medical devices, with special emphasis on Spine Surgery, Neurosurgery, and other skull-based surgeries.

The SonaStar is used by Neuro and General Surgeons for quick and efficient removal of both hard and soft tumors while sparing most vessels.  In addition, OsteoSculpt™ bone sculpting technology can be employed with the SonaStar to safely remove osseous structures, thus providing access to the surgical site.

The BoneScalpel is a tissue specific osteotomy device capable of making precise cuts through bone and hard tissue while largely preserving delicate soft tissue structures.  It offers the convenience and speed of a power instrument without the danger associated with rotary sharps.

"Misonix is quite pleased with the addition of Grand Medical to our ever-expanding roster of Asian specialty distributors.  Their reputation as a high-profile distributor of advanced medical equipment in Taiwan is well known to us," said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix.

About Misonix:

Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices and laboratory equipment.  Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies.  Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications.  Additional information is available on the Company's Web site at www.misonix.com.

With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995.  These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances.  Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships,  regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.  The Company disclaims any obligation to update its forward-looking relationships.

CONTACT: Investor Relations, Kevin McGrath/Cameron Associates, Inc., +1-212-245-4577, Kevin@cameronassoc.com


'/>"/>
SOURCE Misonix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Misonix Announces New Distribution Agreement for Chile
2. Misonix Announces Settlement of PuriCore Litigation, Including Entry into a U.S. Distribution Agreement for PuriCores Advanced Wound Care Product
3. Misonix Announces Exclusive U.S. Distribution Agreement For Advanced Wound Care Product
4. Misonix Schedules Third Quarter 2011 Financial Results Conference Call; May 10, 2011 at 11:30 A.M. Eastern
5. Misonix to Present at the MDB Capital Bright Lights Conference on May 11, 2011
6. Misonix Exhibits at Annual APTA-CSM Meeting
7. Misonix Announces New Distribution Agreement for Colombia
8. Misonix Announces Change in Distribution of BoneScalpel™ Bone Cutting System in the U.S.
9. Misonix to Present at the ROTH Capital Growth Stock Conference on March 15, 2011
10. Misonix Reports Second Quarter and Six Months Fiscal 2011 Financial Results
11. Misonix Announces Completion of Product Registrations in Key Latin American Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... 2017 The global emerging cancer diagnostics market ... from 2016 to 2023 and reach a figure of ... is a chronic disease and is affecting a huge ... market. This report is focused on emerging cancer diagnostics ... is propelled due to factors such as: increasing number ...
(Date:3/28/2017)... 2017  Medeon Biodesign, Inc., a ... to announce that the Company led and successfully ... Inc., a San Jose, CA ... orthopedic extremity applications.  The orthopedic ... due to procedure volume growth, lifestyle influences and ...
(Date:3/28/2017)... -- "US Cancer Generics Market Outlook 2022" report gives ... analysis related to the emergence and integration of ... US. The report analyzes various clinical and non-clinical ... drugs in recent years. The introduction of generics ... for various stake holders involved US cancer drug ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... March 28, 2017 , ... ... the first technology to directly address the resolution to globally reduce the harmful ... a patented compound of FDA and TTB approved ingredients that when infused into ...
(Date:3/28/2017)... ... March 28, 2017 , ... Resoundant, Inc., the developer of ... Siemens Healthineers annual customer education symposium, a world-class learning conference that offers educational ... 27 - 31, 2017 at the Atlanta Marriott Marquis in Atlanta, Georgia. , ...
(Date:3/28/2017)... ... March 29, 2017 , ... The Thyroid Secret is a ... FASCP. The program was recently launched on March 1, and Dr. Wentz discussed ... , Dr. Izabella Wentz is a licensed pharmacist and a foremost thyroid ...
(Date:3/28/2017)... Seattle, WA (PRWEB) , ... March 28, 2017 ... ... reach a 22% share of all holidays (IBT World Travel Trends Report). As ... physically challenging, include a range in temperatures, and prolonged sun exposure. In response, ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... advancing the science and clinical practice of radiosurgery, announced today the publication ... multi-institutional, observational registry established to standardize data collection from patients treated with ...
Breaking Medicine News(10 mins):